|
Jerry Treppel
Chairman of Board of Directors
Jerry Treppel has served as the managing member of Wheaten
Capital Management LLC, a capital management company focusing on investments in
the health care sector, since 2003. In October 2008, Mr. Treppel was also
appointed managing director of Ledgemont Capital Group LLC, a boutique merchant
bank that provides access to capital and corporate advisory services to public
and private companies. Over the past 20 years, Mr. Treppel was an equity
research analyst focusing on the specialty pharmaceuticals and generic drug
sectors at several investment banking firms including Banc of America
Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co.
He previously served as a healthcare services analyst at various firms,
including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from
Rutgers College, an MHA in Health Administration from Washington University, and
an MBA in Finance from New York University. Mr. Treppel has been a
Chartered Financial Analyst *CFA) since 1988.
Barry Dash, Ph.D.
Director
Dr.Barry Dash has served as a Director since April 2005, a Member of the Audit
Committee since April 2005, a Member of the Nominating Committee since April
2005 and a Member of the Compensation Committee since June 2007. Dr. Dash has
been since 1995 President and Managing Member of Dash Associates, L.L.C., an
independent consultant to the pharmaceutical and health industries. From 1983
to 1996 he was employed by American Home Products Corporation (now known as
Wyeth) its Whitehall-Robins Healthcare Division, initially as Vice President of
Scientific Affairs, then Senior Vice President of Scientific Affairs and then
Senior Vice President of Advanced Technologies during which time he personally
supervised six separate departments: Medical and Clinical Affairs, Regulatory
Affairs, Technical Affairs, Research and Development, Analytical R&D and Quality
Management/Q.C. Dr. Dash had been employed by the Whitehall Robins Healthcare
Division from 1960 to 1976, during which time he served as Director of Product
Development Research, Assistant Vice President of Product Development and Vice
President of Scientific Affairs. Dr. Dash had been employed by J.B. Williams
Company (Nabisco Brands, Inc.) from 1978 to 1982. From 1976 to 1978 he was Vice
President, Director of Laboratories of the Consumer Products Division of
American Can Company. He currently serves on the board of GeoPharma, Inc. (NASDQ:
GORX) Dr. Dash holds a Ph.D. from the University of Florida and M.S. and B.S.
degrees from Columbia University where he was Assistant Professor at the College
of Pharmaceutical Sciences from 1956 to 1960. He is a member of the American
Pharmaceutical Association, the American Association for the Advancement of
Science and the Society of Cosmetic Chemist, American Association of
Pharmaceutical Scientists, Drug Information Association, American Foundation for
Pharmaceutical Education, and Diplomate American Board of Forensic Examiners.
He is the author of scientific publications and patents in the pharmaceutical
field.
Chris Dick
Chief Operating Officer & President
Director
Chris Dick joined Elite in November of 2002 as Vice President of
Corporate Development. He directs licensing and business development activities
for Elite. He joined Elite from Elan Drug Delivery, Inc. where he served as
Director of Business Development. While in this position he was responsible for
licensing and business development of Elan’s portfolio of drug delivery
technologies. Prior to Elan, Mr. Dick was Manager of Business Development and
Marketing for EnTec, a drug delivery business unit within FMC Corporation’s
Pharmaceutical Division. Mr. Dick held various other business and technical
positions at FMC including Manager of Marketing for the FMC’s pharmaceutical
functional coatings product line. Mr. Dick received an M.B.A. from Stern School
of Business, New York University and a B.S. and M.S. in Chemical Engineering
from Cornell University
Ashok G. Nigalaye, Ph.D.
Chief Scientific Officer
Director
Dr. Ashok G. Nigalaye has served as a Director since June
24, 2009. Dr.. Nigalaye was elected as a member of Elite’s Board in June 2009
as one of three directors designated by Epic pursuant to the terms of the Epic
Strategic Alliance Agreement. Since July 2008, Dr. Nigalaye has been the
President and Chief Executive Officer of Epic Pharma LLC, a manufacturer of
generic pharmaceuticals and Elite’s strategic partner pursuant to the Epic
Strategic Alliance Agreement. From August 1993 to February 2008, Dr. Nigalaye
served as Vice President of Scientific Affairs and Operations of Actavis Totowa
LLC, a manufacturer of generic pharmaceuticals, where he was responsible for
directing and organizing company activities relating to pharmaceutical drug
manufacturing, regulatory affairs and research and development. Dr. Nigalaye
currently serves as a director of GTI Inc., a privately held company.
Mr. Nigalaye holds a B.S. in Pharmacy from the
University of Bombay, an M.S. in Industrial Pharmacy from Long Island
University, and a Ph.D. in Industrial Pharmacy from St. John’s University. Dr.
Nigalaye is also a licensed pharmacist in the State of New York.
Jeenarine Narine
Director
Jeenarine
Narine has served as a Director since June 24, 2009. Mr. Narine was elected as
a member of Elite’s Board in June 2009 as one of three directors designated by
Epic pursuant to the terms of the Epic Strategic Alliance Agreement. Since July
2008, Mr. Narine has been the Executive Vice President of Manufacturing and
Operations of Epic Pharma LLC, a manufacturer of generic pharmaceuticals and
Elite’s strategic partner pursuant to the Epic Strategic Alliance Agreement, in
which capacity he oversees all manufacturing operations. Mr. Narine is also the
current President of Eniran Manufacturing Inc., a contract manufacturer of
dietary and nutritional supplements, and has held such office since 2000. In
addition, Mr. Narine has been since 1989 the President of A&J Machine Inc., a
company owned by Mr. Narine that is engaged in the sales of new and used
pharmaceutical manufacturing equipment. In addition to this professional
experience, Mr. Narine graduated from the Guyana Industrial Institute, where he
studied Metalology and Welding..
Ram Potti
Director
Ram Potti has served as a Director since June 24,2009. Mr.
Potti was elected as a member of Elite's Board in June 2009 as one of three
directors designated by Epic pursuant to the terms of the Epic Strategic
Alliance Agreement. Since July 2008, Mr. Potti has been the Vice President of
Business Development of Epic Pharma LLC, a manufacturer of generic
pharmaceuticals and Elite’s strategic partner pursuant to the Epic Strategic
Alliance Agreement, in which capacity he handles the company’s new ventures and
products. Mr. Potti is also the founder and current President of RSMB
Investments LLC, an investment company that specializes in startup ventures in
the healthcare and technology sectors. In addition, from 2002 to 2006, Mr.
Potti was the President and Chief Operating Officer of Trigen Laboratories, a
company which he founded that manufactures generic pharmaceutical products. Mr.
Potti holds a B.S. in Chemistry from the University of Kerala, St. Albert’s
College.
Jeffrey Whitnell
Director
Jeffrey Whitnell has served as a
Director since October 2009. Based on information available to the Board, the
Board believes that Mr. Whitnell meets the requirements of an “audit committee
financial expert” as defined under applicable rules under the Securities
Exchange Act of 1934, as amended. Mr. Whitnell previously served as Chief
Financial Officer and Senior Vice President of Finance at Akorn, Inc. between
June 2004 to June 2009. Prior to that, Mr. Whitnell was Vice President of
Finance and Treasurer for Ovation Pharmaceuticals from 2002 to April 2004 and
Vice President of Finance and Treasurer for MediChem Research from 1997 to
2001. Before 1997, he held various finance positions at Akzo Nobel and
Motorola. Mr. Whitnell began his career as an auditor at Arthur Andersen & Co.
He is a certified public accountant and holds an M.B.A. in Finance from
University of Chicago and a B.S. in Accounting from University of Illinois.
Officers:
Carter J. Ward, CPA, CSCP
Chief Financial Officer
Carter Ward
joined Elite in July of 2009 as Chief Financial Officer. Mr. Ward is a
certified public accountant, graduated summa cum laude from Long Island
University, Brooklyn, NY. For most of the past ten years, Mr. Ward’s experience
has been in the generic pharmaceutical industry, most recently filling multiple
finance and supply chain leadership roles with Actavis Group and its U.S.
subsidiary, Amide Pharmaceuticals. Earlier in his career, he was the Chief
Financial Officer for Positive Healthcare/Ceejay Healthcare, a U.S.-Indian joint
venture engaged in the manufacture and distribution of generic pharmaceuticals
and nutraceuticals in India. Mr. Ward began his career in public accounting
with KPMG.
|